Medicare Part B Rates For Bundled Drugs Might Be Improved With “Exceptions” Process – MedPAC
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS should consider a process to allow revisions of Part B average sales prices for drugs sold through bundled arrangements, to enhance the accuracy of ASPs, the advisory panel group suggests to agency.